Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Köln, Universität zu Köln, Dissertation, 2024
- Keyword
-
Apoptosis
Inhibitor
Krebs
- Event
-
Veröffentlichung
- (where)
-
Köln
- (who)
-
Universitäts- und Stadtbibliothek Köln
- (when)
-
2024
- Creator
-
Breull-Wierschem, Leonie
- Contributor
-
Frenzel, Lukas-Peter
Kashkar, Hamid
- URN
-
urn:nbn:de:hbz:38-742888
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Breull-Wierschem, Leonie
- Frenzel, Lukas-Peter
- Kashkar, Hamid
- Universitäts- und Stadtbibliothek Köln
Time of origin
- 2024
Other Objects (12)
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Venetoclax - ein neuer Therapiestandard in der AML
Venetoclax - Standard in der Erstlinientherapie unfitter AML-Patienten
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Venetoclax - ein neuer Therapiestandard in der AML
Venetoclax - Standard in der Erstlinientherapie unfitter AML-Patienten
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Venetoclax - ein neuer Therapiestandard in der AML
Venetoclax - Standard in der Erstlinientherapie unfitter AML-Patienten
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment